How a bacterial enzyme helps germs quickly become resistant to antibiotics

An Analysis of ICE R391 Pathogen-encoded Rum DNA Polymerase in Generating Mutations Driving Rapid Acquisition of Antibiotic Drug Resistance in Diverse Recipient Bacterial Species

NIH-funded research University of Southern California · NIH-11304577

This project explains how a bacterial enzyme causes germs to mutate and become resistant to antibiotics, which could help people with infections that don't respond to medicines.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Southern California NIH-funded
Lab location1 site (Los Angeles, UNITED STATES)
Project IDNIH-11304577 on NIH RePORTER

What this research studies

Researchers will grow different bacterial species in the lab and introduce the R391 mobile element that carries the Rum DNA polymerase to see how it changes bacterial DNA. They will change and test the bacterial RecA protein, focusing on a specific methionine (M197), to learn how it teams up with Rum pol to create mutations. The team will use DNA sequencing to map where mutations happen and will test whether those mutations make bacteria resistant to common antibiotics. Results will be compared across several recipient species to determine how broadly this mechanism speeds up antibiotic resistance.

Who could benefit from this research

Good fit: People with infections that don't respond to standard antibiotics are the group most likely to benefit from insights produced by this work.

Not a fit: Patients with non-bacterial illnesses or infections not driven by antibiotic resistance are unlikely to receive direct benefit from this laboratory-focused research.

Why it matters

Potential benefit: If successful, this work could reveal a common mechanism that drives rapid antibiotic resistance and point to ways to prevent or slow resistance, helping future patients get more effective treatments.

How similar studies have performed: Related research has shown that error-prone polymerases can drive mutations and resistance, but the specific role of Rum pol across diverse bacterial species and the RecA M197 interaction is less well tested.

Where this research is happening

Los Angeles, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.